喉癌组织中尿激酶型纤溶酶原激活剂的表达及其预后评估价值

目的研究喉癌组织中尿激酶型纤溶酶原激活剂（urokinase plasminogen activator,uPA）的表达及其在喉癌患者临床预后评估中的价值。方法应用组织芯片及免疫组化技术Envision二步法检测uPA在79例喉癌切除标本组织中的表达情况并结合临床随访,分析其与临床病理参数及患者预后的关系。结果 uPA的高表达与喉癌的淋巴结转移有关（χ2=4.145,P=0.042）。uPA阳性者5年生存率为23.3%,uPA阴性者5年生存率为46.9%,两者差异具有统计学意义（χ2=4.402,P〈0.05）。从uPA相关的生存曲线上看,uPA阴性患者的生存率明显高于uPA阳性患者。结论分析uPA可能有助于评估喉癌发生转移的危险性,对于评估临床预后有重要参考价值。

Expression of urokinase plasminogen activator and its prognostic value in carcinoma of human larynx

Objective To investigate the expression of urokinase plasminogen activator （uPA） in laryngeal carcinoma and to evaluate its clinical value in prognosis. Methods The expression of uPA was determined by immunohistochemistry with Envision two-step method on tissue microarray slides in 79 patients with laryngeal carcinoma. All patients were followed up and their prognostic factors were analyzed. Results The expression of uPA in laryngeal carcinoma tissue was statistically associated with lymph node metastases （X2 = 4. 145, P = 0. 042 ）. The positive or enhanced expression of uPA was associated with the survival rate of patients with laryngeal carcinoma （X2 =4. 402 ,P = 0. 036）. The 5-year survival rate of the patients with uPA-positive tumors was 23. 3% , while that with uPA-negative tumors was 46.9%. The difference was statistically significant （X2 = 4. 402, P 〈 0.05 ）. The survival rate of the patients with uPA-negative tumors was significantly higher than that with uPA-positive tumors according to the Kaplan curve associated with uPA. Conclusion The analysis of uPA expression in the laryngeal carcinoma tissue may be useful for predicting the patient＇ s prognosis.